Fully-human 유래 및 TCR 항체 플랫폼

이중 특이항체

이중 특이성 항체(BsAbs)는 두 개의 항원을 동시에 타겟으로 하여, 향상된 특이성, 내성 극복 및 질병 이질성 해결을 가능하게 합니다. 이를 통해 약리학적 특성을 최적화하고, 비특이적 효과를 줄이며, 경로 차단 및 면역 세포 재지정과 같은 다양한 메커니즘을 지원하여 광범위한 치료 잠재력을 발휘합니다.
  • 여러 종양 유발 단백질을 동시에 타겟으로 하여 약물 내성을 극복할 수 있는 가능성이 있습니다.
  • 두 개의 타겟을 동시에 발현하는 세포를 인식하여 종양 특이성을 높이고 비특이적 독성을 줄일 수 있습니다.
  • 두 개의 선택된 타겟의 조합은 내화성을 증가시켜 종양 살상 효과를 강화합니다.
  • 10+
    완전 인간 이중특이성 항체
  • 10+
    TCR 모방 자산

이 페이지에서

  • Biocytogen BsAb 플랫폼 주요 강점
  • Biocytogen의 RenLite 기반 BsAb 개발 플랫폼
  • 파트너십을 위한 Off-the-Shelf BsAb 자산
  • FAQs

웨비나

모두 보기

    포스터

    모두 보기

      Biocytogen BsAb 플랫폼 주요 강점

      • 다양한 포맷 설계: Knobs-into-Holes 등의 기술을 활용하여 scFv, peptide, VHH, cytokine 등 다양한 기능성 구성 요소를 적용한 유연한 BsAb 포맷 설계가 가능합니다.
      • Common Light Chain 기반의 효율적인 BsAb 개발: Fully human common light chain 항체를 기반으로 효율적이고 정밀한 이중특이성 항체 조립이 가능하며, light chain mispairing을 최소화할 수 있습니다.
      • 높은 다양성과 친화도를 갖춘 항체 발굴: RenLite KO mouse와 Beacon technology를 결합하여 높은 항체 다양성 및 우수한 결합 친화도(affinity)를 갖는 항체를 발굴합니다.
      • In vivo 기반의 확장 가능한 검증: 강력한 in vivo 검증 시스템을 활용하여 유효성과 안전성을 갖춘 최적의 target combination을 선별합니다.
      • 이중기능성 분자 개발: Antibody-Cytokine Molecule을 개발하여 우수한 상호작용 및 시너지 효과를 구현하고, cytokine 기반 치료제의 druggability 향상을 지원합니다.

      Biocytogen의 RenLite 기반 BsAb 개발 플랫폼

      RenLite 기반 BsAb 개발 플랫폼

      BsAb developed from RenLite mice

      파트너십을 위한 Off-the-Shelf BsAb 자산

      Format Therapeutic Area Product Number Target(s) Immunization
      • Development
      • Hits
        selection
        Leads
        selection
        Candidate
        selection
      Preclinical IND Phase I Status
      BsAb Oncology YH008 PD-1 x CD40
      Partnered ex-China rights available
      BsAb Oncology YH006 OX40 x CTLA4
      BsAb Oncology BCG021 4-1BB x CD40
      BsAb Inflammation and Autoimmunity BCG028 OX40 x OX40
      BsAb Oncology - CD40 x CTLA4
      BsAb Oncology BCG051 GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity - IL4RA x KIT
      BsAb Inflammation and Autoimmunity - IL13 x TSLP
      BsAb Inflammation and Autoimmunity - IL17A x IL17F x IL4RA
      BsAb Oncology - B7-H3 x FN1
      TCE Oncology - CDH17 x CD3 x CD28
      TCE Oncology - STEAP1 x CD3e
      TCE Oncology BCG024 DLL3 x CD3 x 4-1BB
      Tri-Ab Oncology BCG038 EGFR x VEGFA x CD98
      Tri-Ab Oncology - PD-L1 x CD98 x VEGFA
      Tri-Ab Inflammation and Autoimmunity - C2 x FCGRT x ALB
      Tri-Ab Oncology - PD-L1 x IL11 x VEGFA
      Tri-Ab Oncology - PD-L1 x VEGFA x IL27R

      Frequently Asked Questions (FAQs) About Bispecific Antibody Platform

      1. What is a bispecific antibody, and what unique mechanisms of action does it offer beyond conventional monoclonal antibodies?

      A bispecific antibody (BsAb) recognizes two different antigens or epitopes within a single molecule. This dual specificity enables novel therapeutic mechanisms beyond conventional monospecific antibodies, including: dual pathway blockade, receptor co-localization or clustering, and immune-cell redirection such as T-cell engagers (TCEs).

      2. What antibody formats and modalities does Biocytogen’s bispecific antibody platform support?

      Biocytogen’s platform supports fully human bispecific, biparatopic, and multispecific antibody formats. Flexible architectures can incorporate common light chain antibodies, VHHs, scFvs and cytokines to meet diverse therapeutic design needs. In addition to unconjugated BsAbs and BpAbs, Biocytogen has also established a platform that enables selected bispecific antibody backbones to be further developed into bispecific antibody-drug conjugates (BsADCs).

      3. What are the advantages of developing biparatopic antibodies (BpAbs)?

      BpAbs bind two distinct, non-overlapping epitopes on the same antigen to overcome the limitations of conventional monoclonal antibodies. Key advantages include:
      • Enhanced target engagement: Achieves greater receptor occupancy and more complete ligand blockade compared with single-epitope antibodies.
      • Differentiated functional activity: Modulation of receptor clustering, internalization, or signaling to enhance therapeutic activity.
      For example, Biocytogen’s BCG028, a biparatopic OX40 antagonist, leverages dual-epitope binding to reduce OX40-mediated T-cell costimulatory signaling, delivering superior in vivo efficacy in preclinical models.

      4. How does Biocytogen address chain mispairing in bispecific antibody generation?

      Biocytogen combines complementary engineering strategies to simplify fully human bispecific and multispecific antibody assembly:
      • RenLite®-derived common light-chain antibodies: Use a shared light chain to avoid mispairing between different heavy and light chains.
      • Fully human VHH antibody integration: Provide compact, modular single-domain building blocks that require no light chain, reducing pairing complexity.
      • Knobs-into-Holes (KIH) engineering: Applied to promote correct pairing between two different heavy chains.
      Together, these approaches address distinct chain-pairing challenges, simplifying antibody assembly and supporting favorable developability.

      5. How does Biocytogen discover and evaluate fully human bispecific antibody candidates?

      Biocytogen uses RenLite® or RenLite® target-gene KO mice to generate fully human common light-chain antibodies. Beacon-based single-cell screening with AI-powered selection supports accelerated candidate identification. Candidates are then evaluated in in vivo studies, including target-humanized mouse models, to assess efficacy and safety with high translational potential.

      6. What off-the-shelf antibody libraries does Biocytogen offer for bispecific antibody development?

      Biocytogen offers more than 200 TAA-specific fully human antibody backbones for plug-and-play bispecific antibody (BsAb) development. Through RenSuper™ Workstation, partners can also access broader antibody libraries spanning over 1,000 targets to identify building blocks for customized and scalable BsAb development.